Ardelyx, Inc.

ARDX Healthcare Biotechnology

Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

3.09 0.18 −5.50%
Market cap
$814.9M
P/E
0.0×
Fwd P/E
−122×
Dividend yield
—
F-score
2/9
Altman Z
1.12
Beneish M
−2.40
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 3 2 5

+8 more TTM periods

ROE
(38.61%) (39.46%) (36.21%) (36.18%)
ROA
(10.68%) (12.69%) (13.14%) (13.24%)
ROIC
(18.62%) (20.50%) (24.37%) (20.86%)
Return on Tangible Assets
(17.88%) (21.17%) (20.82%) (19.73%)
Average Days of Receivables
81.24 70.70 64.38 70.22
Free Cash Flow per Share
(0.07) (0.15) (0.18) (0.23)
Free Cash Flow
(17.92) (37.50) (43.97) (55.35)
Capital Expenditures
(0.60) (1.24) (1.49) (1.72)
Other line items
Cash ROIC
(2.62%) (6.35%) (6.93%) (9.24%)
Accounts Receivable Turnover
5.54 6.61 6.29 6.14
Accounts Payable Turnover
0.85 1.53 2.24 2.74
Inventory Turnover
1.06 1.38 2.03 2.57
Average Days of Payables
551.93 321.15 177.57 142.96
Days of Inventory on Hand
371.57 259.07 163.73 195.68
Tax Rate
0.00 0.00 0.02 0.02
Research and Development Expense of Revenue
19.34% 17.95% 17.56% 15.65%
Selling, General and Administrative Expense of Revenue
82.89% 83.31% 82.79% 82.09%
Share Based Compensation of Revenue
12.12% 11.93% 12.02% 11.65%
Interest Coverage
(1.24) (1.29) (1.44) (1.42)
Operating CF/Net income
0.31 0.62 0.69 0.95
Depreciation/Fixed assets
1.88 1.68 1.40 1.28
Capex/Depreciation
(0.18) (0.37) (0.49) (0.65)
Revenue per Share
1.82 1.74 1.69 1.65
Operating CF per Share
(0.07) (0.15) (0.18) (0.22)
Capex per Share
0.00 0.00 (0.01) (0.01)
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates